Eliem Therapeutics, Inc. announced On June 12, 2024, the Eliem board of directors appointed Aoife Brennan as Chief Executive Officer of Eliem, subject to and contingent and effective upon the closing of the Acquisition (the Effective Date). Dr. Brennan, age 48, was most recently President and Chief Executive Officer of Synlogic, Inc. from October 2018 to March 2024. Prior to joining Synlogic, Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen Inc. where her responsibilities included the global marketing approvals of ALPROLIX, ELOCTATE and SPINRAZA as well as the advancement of several early-phase programs and external collaborations.

She has served as a director of Cerevance, LLC since January 2020 and as a director of Fibrogen Inc. since August 2020. Dr. Brennan also served as a director of Synlogic from October 2018 to March 2024, and as a director of Ra Pharmaceuticals, Inc. from September 2018 through its acquisition in April 2020. Dr. Brennan holds a medical degree from Trinity College, Dublin, Ireland and completed residency and fellowship training in general internal medicine and endocrinology.

She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program. As a result of Dr. Brennan?s appointment as Chief Executive Officer, Andrew Levin, Eliem?s Executive Chairman, will cease to serve as Eliem?s principal executive officer, effective as of the Effective Date. Dr. Levin will continue to serve as Eliem?s principal financial officer.